公司事件 - Pacira BioSciences公司因专利无效导致股价大幅下跌 公司的主要产品Exparel的专利被法院判定无效 导致股价从2024年8月8日的22.36美元/股暴跌至2024年8月9日的11.70美元/股 单日跌幅超过47% [3] - Exparel是Pacira BioSciences公司的主要收入来源 占公司总收入的80% 专利无效可能导致更多仿制药进入市场 并增加未来的诉讼费用 [3] 法律诉讼 - Gross Law Firm正在征集在2023年8月2日至2024年8月8日期间购买Pacira BioSciences公司股票的股东参与集体诉讼 股东需在2025年3月14日前登记 [1][3][4] - 参与集体诉讼的股东将获得案件进展的实时更新 无需支付任何费用或承担义务 [4] 公司影响 - Pacira BioSciences公司的其他专利有效性可能受到质疑 这可能进一步影响公司的市场竞争力和财务状况 [3]

公司诉讼事件 - Zeta Global Holdings Corp (ZETA) 的股东在2024年2月27日至2024年11月13日期间购买公司股票的股东被鼓励联系Gross Law Firm，以参与可能的集体诉讼 [1][3] - 诉讼指控Zeta在集体诉讼期间发布了重大虚假和/或误导性声明，未披露以下内容：1) 使用双向合同人为夸大财务结果 2) 进行往返交易人为夸大财务结果 3) 利用掠夺性同意农场收集用户数据 4) 这些同意农场几乎推动了Zeta的全部增长 5) 因此，公司关于业务、运营和前景的正面声明具有重大误导性和/或缺乏合理依据 [3] - 股东需在2025年1月21日前注册参与此集体诉讼，注册后将通过投资组合监控软件获得案件进展更新 [4] 律师事务所信息 - Gross Law Firm是一家全国知名的集体诉讼律师事务所，致力于保护因欺骗、欺诈和非法商业行为而遭受损失的投资者权益 [5] - 该律所位于纽约市，联系方式包括地址、电子邮件和电话 [6]

NEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of AstraZeneca PLC (NASDAQ: AZN). Shareholders who purchased shares of AZN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/astrazeneca-plc-loss-submission-form-2/?id=122775&from=3 CLASS PERIOD: February 23, ...

NEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Marqeta, Inc. (NASDAQ: MQ). Shareholders who purchased shares of MQ during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/marqeta-inc-loss-submission-form/?id=122774&from=3 CLASS PERIOD: May 7, 2024 to November ...

NEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Match Group, Inc. (NASDAQ: MTCH). Shareholders who purchased shares of MTCH during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/match-group-inc-loss-submission-form-3/?id=122776&from=3 CLASS PERIOD: May 2, 20 ...

NEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Xerox Holdings Corporation (NASDAQ: XRX). Shareholders who purchased shares of XRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/xerox-holdings-corporation-loss-submission-form/?id=122773&from=3 CLASS P ...

NEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Customers Bancorp, Inc. (NYSE: CUBI). Shareholders who purchased shares of CUBI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/customers-bancorp-inc-loss-submission-form/?id=122770&from=3 CLASS PERIOD: M ...

NEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC). Shareholders who purchased shares of RVNC during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/revance-therapeutics-inc-loss-submission-form-2/?id=122771&from=3 CLASS ...

NEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Pacira BioSciences, Inc. (NASDAQ: PCRX) between August 2, 2023 and August 8, 2024, both dates inclusive (the “Class Period”). A lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 14, 2025. SO WHAT: If you purchased Pacira securities during the Class Period, ...

NEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Visa Inc. (NYSE: V). Shareholders who purchased shares of V during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/visa-inc-loss-submission-form/?id=122767&from=3 CLASS PERIOD: November 16, 2023 to September 23, ...